According to a recent market survey conducted by Future Market Insights (FMI), the global Atopic Dermatitis Treatment market size was valued at US$ 5.2 Billion in 2021 and is expected to reach US$ 7.6 Billion by 2029. FMI’s new market research report on this industry includes a global analysis of the years 2014 to 2021 and an assessment of opportunities from 2022 to 2029.
The report provides critical insights into the Atopic Dermatitis Treatment market and predicts significant growth during the forecast period of 2022 to 2029. This growth is attributed to various factors, such as increasing prevalence, promising pipeline molecules, higher treatment compliance, increasing access to treatment medication in developing countries, favorable reimbursement policies, increasing government support for research and development, and advancing technology.
Request a Report Sample and Gain a Competitive Advantage@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3097
Corticosteroids Remain the Drug of Choice
Corticosteroids are considered the first-line treatment for inflammation and pain alleviation. These drugs have been shown to reduce tingling, allergic reactions, swelling, and redness.
Around 30 corticosteroid compounds have been approved for the treatment of atopic dermatitis, with ‘hydrocortisone’ being the first. Furthermore, rising innovation has led in the introduction of topical non-corticosteroid immunomodulators and target medicines, such as pimecrolimus and tacrolimus, which is expected to fuel the expansion of the Atopic Dermatitis Treatment market. Furthermore, topical corticosteroids are predicted to play essential roles in the treatment of atopic dermatitis.
North America to Offer High Sales Opportunities
Growth prospects of the Atopic Dermatitis Treatment market are likely to be high in North America over the forecast period of 2022 to 2029. Factors such as, greater treatment awareness among the patient population across the United States and Canada, early adoption of novel prescriptions, advanced healthcare infrastructure, better and favorable reimbursement policies, and increasing business associations of pharmaceutical organizations with contract research organizations in developing markets will continue to propel the Atopic Dermatitis Treatment market growth.
Despite the fact that the U.S and Canada deal with heavy investment in healthcare infrastructure as well as per capita expenditure, there are increasing number of campaigns organized each year by specific establishments, for example, National Eczema Associations, the PAN Foundation, and pharmaceutical organizations, which are envisaged to work to the advantage of several market vendors.
Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-3097
Hospital Pharmacies – The Key Distribution Channel for Atopic Dermatitis Treatment
Sales of medication for Atopic Dermatitis Treatment through hospital pharmacies will continue to account for relatively high share in the market, as they can stock large range of prescription medicines, including progressively specific and investigational medications. Hospital pharmacies may provide a tremendous amount of medications every day, which is distributed to wards and to intensive care units as per the patient’s prescription schedule.
Topical Drug Administration- A Preferred Mode
Topical mode of administration remains highly preferred among the patient pool of atopic dermatitis. Advent of topical non-corticosteroids immunomodulators is the major factor for the growth in the demand for Atopic Dermatitis Treatment. As topical administration gains prominence, major corticosteroids medications are formulated as topical, in addition to their benefits over oral dosage form.
Atopic Dermatitis Treatment Market: Vendor Insights
The report highlights some of the prominent market players, who have established themselves as leaders in the global Atopic Dermatitis Treatment market. Some of the examples of key players in the global Atopic Dermatitis Treatment market are Sanofi S.A., Galderma S.A., Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals Inc., Astellas Pharma, Inc., Anacor Pharmaceuticals, Inc., Regeneron Pharmaceuticals, and Valeant Pharmaceuticals International, Inc.
Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/3097
Atopic Dermatitis Treatment Market by Category
By Product
- Corticosteroids
- Calcineurin Inhibitors
- Immunosuppressants
- Biologic Therapy
- PDE-4 Inhibitor
- Antibiotics
- Antihistamines
- Emollients
By Indication
- Topical
- Oral
- Injectable
By End-User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Dermatology Clinics
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs